Shamburg News · 8-K filed Oct 19, 2026, 9:15 AM EDT

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter

BCDA · BioCardia, Inc.

  • Other event
  • Materiality: medium

On October 19, 2026, BioCardia, Inc. announced that the FDA accepted its revised De Novo pre-submission package for marketing clearance of its Helix transendocardial delivery catheter. The company expects FDA substantive review with written feedback and a meeting to discuss approval via the De Novo pathway this quarter. The filing was furnished under Item 8.01 with the press release attached as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001437749-26-032887.

Written from the filing by Shamburg Markets. Figures are as reported by the company.